Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
出版年份 2014 全文链接
标题
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
作者
关键词
-
出版物
Therapeutic Advances in Medical Oncology
Volume 6, Issue 5, Pages 229-239
出版商
SAGE Publications
发表日期
2014-08-06
DOI
10.1177/1758834014544121
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Ovarian Cancer, Version 2.2013
- (2017) Robert J. Morgan et al. Journal of the National Comprehensive Cancer Network
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data
- (2013) F. A. Raja et al. ANNALS OF ONCOLOGY
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) J. A. Ledermann et al. ANNALS OF ONCOLOGY
- PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer
- (2013) R. Wendel Naumann et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
- (2013) Noriyuki Katsumata et al. LANCET ONCOLOGY
- The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
- (2012) L. C. Hanker et al. ANNALS OF ONCOLOGY
- Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
- (2012) U Wagner et al. BRITISH JOURNAL OF CANCER
- Evolving concepts in the management of drug resistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance
- (2012) David J. Pinato et al. CANCER TREATMENT REVIEWS
- Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?
- (2012) Georgia A. McCann et al. GYNECOLOGIC ONCOLOGY
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
- (2012) Kathryn Alsop et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer
- (2012) Nicoletta Colombo et al. JOURNAL OF CLINICAL ONCOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated Analysis of Gene Expression Profiles Associated with Response of Platinum/Paclitaxel-Based Treatment in Epithelial Ovarian Cancer
- (2012) Yong Han et al. PLoS One
- A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer
- (2011) G. Rustin et al. ANNALS OF ONCOLOGY
- Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
- (2011) R Y Zang et al. BRITISH JOURNAL OF CANCER
- Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
- (2011) Timothy A. Yap et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Overview of anti-angiogenic agents in development for ovarian cancer
- (2011) Robert A. Burger GYNECOLOGIC ONCOLOGY
- Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
- (2011) Gordon John Sampson Rustin et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Clinical Trials in Recurrent Ovarian Cancer
- (2011) Michael Friedlander et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer
- (2011) Gavin C.E. Stuart et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study
- (2011) Walter H Gotlieb et al. LANCET ONCOLOGY
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
- (2010) S. B. Kaye et al. ANNALS OF ONCOLOGY
- Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer
- (2010) Christopher S. Bryant et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
- (2010) Dimitrios Bafaloukos et al. BMC Medicine
- Epithelial Ovarian Cancer
- (2010) JS Tanguay et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
- (2010) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
- (2010) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
- (2010) Gordon JS Rustin et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal Carcinomatosis
- (2009) P. Harter et al. ANNALS OF SURGICAL ONCOLOGY
- Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer
- (2009) R Sharma et al. BRITISH JOURNAL OF CANCER
- A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer
- (2009) Ignace Vergote et al. EUROPEAN JOURNAL OF CANCER
- Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)
- (2009) Werner Meier et al. GYNECOLOGIC ONCOLOGY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum Resistance: The Role of DNA Repair Pathways
- (2008) L. P. Martin et al. CLINICAL CANCER RESEARCH
- Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200)
- (2007) David S. Alberts et al. GYNECOLOGIC ONCOLOGY
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started